miltefosine has been researched along with Lupus Erythematosus, Systemic in 1 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villamil-Gómez, WE | 1 |
| Calderón-Gomezcaseres, Á | 1 |
| Rodriguez-Morales, AJ | 1 |
1 other study available for miltefosine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America.
Topics: Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Visceral; Lupus Erythematosus, Systemi | 2019 |